Since 1998, Emergent BioSolutions has been a trusted, go-to source for solving some of the most complex and critical challenges in public health. From initial R&D and clinical studies to formulation, manufacturing and packaging, our experienced CDMO team at Emergent is ready to serve as your trusted guide from molecule to market.

With a demonstrated expertise in preparedness for public health threats, Emergent BioSolutions has deployed its resources – capacities, capabilities, and expertise – to attack the current COVID-19 pandemic. Partnering with fellow innovators, our CDMO business is providing development and manufacturing services for several clinical trial vaccine candidates.

Download our OnDemand Webinar, Rapid Readiness: How Drug Developers Can Maximize Capacity, Capabilities, and Expertise For Pandemic Response, to gain insight on the progress surrounding this new challenge and learn how pharma and biotech companies are working together to speed development, making both vaccines and treatments available to those in need.

While we are most known for the rapid deployment of our development and manufacturing capabilities to combat public health threats, Emergent CDMO supports a broad portfolio of preclinical through commercial programs, and can guide your project successfully through all the possible challenges along the molecule to market pathway.

Our development and manufacturing capabilities include:

• Mammalian

• Microbial

• Viral

• Small molecule

• Plasma